0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAP

LAP

LAP Molecule Information

Name:Transforming growth factor beta 1
Target Synonym:TGFB;Latency-associated peptide;TGFB1;LAP;TGF-beta-1;Transforming growth factor beta-1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

LAP Molecule Synonym Name

TGFB1,CED,DPD1,LAP,TGF¦Â1,TGF-beta

LAP Molecule Background

Transforming growth factor beta 1 ( TGFB1) is also known as TGF-¦Â1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

LAP References

LAP Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirfenidone S-7701; AMR-69; F-647; GP-101; RO-0220912; S-770108 Approved Intermune, Shionogi, Shanghai Genomics Pirfenidone 日本 Idiopathic pulmonary fibrosis (IPF) 盐野义 2008-10-16 00:00:00.0 Idiopathic pulmonary fibrosis (IPF) Details

LAP Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BGC-200134 BGC-200134 Phase Ⅱ BTG plc Multiple sclerosis (MS) Details
Anti-TGF beta monoclonal antibody (Lilly) Phase Ⅱ Lilly Diabetes Details
Vactosertib TEW-7197; NOV-1301; EW-7197,TEW 7197,NOV 1301 Phase Ⅱ MedPacto Myelodysplastic syndrome (MDS) Details
Metelimumab CAT-192; SL-15,SL15 Phase Ⅱ Cambridge Antibody Technology, Genzyme Fibrosis, Systemic sclerosis, Cancer Details
Bintrafusp alfa M-7824; MSB-0011359C Phase Ⅲ Merck Serono, GlaxoSmithKline Non small cell lung cancer (NSCLC), Prostate cancer, Solid tumours, Respiratory papillomatosis, Biliary cancer Details
TJN-598 TJN-598 Phase Ⅱ Tsumura Glomerulonephritis Details
PXS-25 PXS-25,PXS25 Phase Ⅰ Pharmaxis Pulmonary fibrosis Details
STP-705 STP-705LU; STP-705LV; STP-705; STP-705L Phase Ⅱ Sirnaomics, Suzhou Sirnaomics Biopharmaceuticals, Guangzhou Xiangxue Pharmaceuticals Squamous cell cancer, Skin hypertrophic scars Details
PRM-151 PRM-151; rhPTX-2; rhSAP Phase Ⅱ Promedior Kidney disorders, Myelofibrosis, Scars, Idiopathic pulmonary fibrosis (IPF), Non-alcoholic steatohepatitis Details
Mannose phosphate M6P Phase Ⅲ Renovo wound, Dermal scarring Details
盐酸美氟尼酮 Phase Ⅰ Guangzhou Nanxin Pharmaceutical, Central South University Diabetic nephropathy Details
YL-13027 YL-13027 Phase Ⅰ Shanghai Yingli Pharmaceutical Myelodysplastic syndrome (MDS), Solid tumours, Multiple myeloma (MM) Details
Disitertide NAFB-001; P-144; Peptide-144 Phase Ⅱ Digna Biotech, University of Navarra, Flamel Technologies, ISDIN Scleroderma Details
DW-1029M DW-1029M Phase Ⅱ Dong Wha Pharmaceuticals Diabetic nephropathy Details
Yinfenidone Hydrochloride HEC-00000585; HEC-585 Phase Ⅰ HEC Pharm Idiopathic pulmonary fibrosis (IPF) Details
Fluorofenidone AKF-PD,AKFPD Phase Ⅰ Central South University, Dierepharma, Hainan Haiyao Pharma Hepatic fibrosis, Renal fibrosis Details
Nicousamide XLF-III-43 Phase Ⅱ Institute of Materia Medica Chinese Academy of Medical Sciences, Chiatai Tianqing (CTTQ) Diabetic nephropathy, Hypertensive nephropathy Details

This web search service is supported by Google Inc.

totop